SI1687019T1 - Propilen gliko-ki vsebuje peptidne formulacije, ki so optimalne za proizvodnjo in za uporabo v injekcijskih napravah - Google Patents
Propilen gliko-ki vsebuje peptidne formulacije, ki so optimalne za proizvodnjo in za uporabo v injekcijskih napravah Download PDFInfo
- Publication number
- SI1687019T1 SI1687019T1 SI200432419T SI200432419T SI1687019T1 SI 1687019 T1 SI1687019 T1 SI 1687019T1 SI 200432419 T SI200432419 T SI 200432419T SI 200432419 T SI200432419 T SI 200432419T SI 1687019 T1 SI1687019 T1 SI 1687019T1
- Authority
- SI
- Slovenia
- Prior art keywords
- formulation
- propylene glycol
- concentration
- formulation according
- production
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Claims (17)
- PROPILEN GLIKOL-KI VSEBUJE PEPTIDNE FORMULACIJE, KI SO OPTIMALNE ZA PROIZVODNJO IN ZA UPORABO V INJEKCIJSKIH NAPRAVAH PATENTNI ZAHTEVKI1. Farmacevtska formulacija, ki obsega peptid Arg34, Lys26(N£-(Y-Glu(Na-heksadekanoil)))-GLP-1(7-37) in propilen glikol, kjer je naveden propilen glikol prisoten v navedeni formulaciji v končni koncentraciji od 1 mg/ml do 100 mg/ml in kjer ima navedena formulacija pH od 7,0 do 10,0.
- 2. Formulacija po zahtevku 1, kjer je omenjena formulacija primerna za parenteralno dajanje s subkutano, intramuskularno ali intravensko injekcijo s pomočjo brizge, po izbiri peresu-podobne brizge (ang.«pen-like syringe«).
- 3. Formulacija po katerem koli od prejšnjih zahtevkov, kjer je koncentracija propilen glikola od 1 mg/ml do 50 mg/ml.
- 4. Formulacija po katerem koli od prejšnjih zahtevkov, kjer je koncentracija propilen glikola od 5 mg/ml do 25 mg/ml.
- 5. Formulacija po katerem koli od prejšnjih zahtevkov, kjer je koncentracija propilen glikola od 8 mg/ml do 16 mg/ml.
- 6. Formulacija po katerem koli izmed predhodnih zahtevkov, kjer je pH omenjene formulacije 7,0 do 9,5.
- 7. Formulacija po katerem koli od predhodnih zahtevkov, kjer omenjeni peptid sestoji iz Arg34, Lys26 (N£-(Y-Glu(NQ-heksadekanoil)))-GLP-1(7-37).
- 8. Formulacija po zahtevku 7, kjer je pH omenjene formulacije 7,0 do 8,3.
- 9. Formulacija po zahtevku 8, kjer je pH omenjene formulacije 7,3 do 8,3.
- 10. Formulacija po zahtevku 9, kjer je pH omenjene formulacije 8,0 do 8,3.
- 11. Formulacija po katerem koli od predhodnih zahtevkov, ki nadalje obsega konzervans.
- 12. Formulacija po zahtevku 11, kjer je omenjeni konzervans prisoten v koncentraciji od 0,1 mg/ml do 20 mg/ml.
- 13. Formulacija po zahtevku 11 ali 12, kjer je omenjeni konzervans fenol.
- 14. Formulacija po katerem koli od predhodnih zahtevkov, ki nadalje obsega pufer.
- 15. Formulacija po zahtevku 14, kjer je navedeni pufer izbran iz skupine, ki jo sestavljajo glicilglicin, natrijev dihidrogen fosfat, dinatrijev hidrogen fosfat, natrijev fosfat ali njihove zmesi.
- 16. Formulacija po zahtevkih 14, pri čemer je navedeni pufer dinatrijev fosfat dihidrat.
- 17. Formulacija po katerem koli od prejšnjih zahtevkov, kjer je koncentracija omenjenega Arg34, Lys26(N-£-(Y-Glu(N-a-heksadekanoil)))-GLP-1(7-37) od 0,1 mg/ml do 50 mg/ml ali od 0,1 mg/ml do 10 mg/m.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301719 | 2003-11-20 | ||
EP04797453.0A EP1687019B1 (en) | 2003-11-20 | 2004-11-18 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
PCT/DK2004/000792 WO2005049061A2 (en) | 2003-11-20 | 2004-11-18 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1687019T1 true SI1687019T1 (sl) | 2018-04-30 |
Family
ID=34609967
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200432469T SI3300721T1 (sl) | 2003-11-20 | 2004-11-18 | Peptidne formulacije, ki vsebujejo propilen glikol in ki so optimalne za proizvodnjo in uporabo v napravah za injiciranje |
SI200432419T SI1687019T1 (sl) | 2003-11-20 | 2004-11-18 | Propilen gliko-ki vsebuje peptidne formulacije, ki so optimalne za proizvodnjo in za uporabo v injekcijskih napravah |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200432469T SI3300721T1 (sl) | 2003-11-20 | 2004-11-18 | Peptidne formulacije, ki vsebujejo propilen glikol in ki so optimalne za proizvodnjo in uporabo v napravah za injiciranje |
Country Status (20)
Country | Link |
---|---|
US (5) | US8114833B2 (sl) |
EP (3) | EP1687019B1 (sl) |
JP (2) | JP5558655B2 (sl) |
KR (1) | KR101243648B1 (sl) |
CN (4) | CN104826116A (sl) |
AU (1) | AU2004290862B2 (sl) |
BR (1) | BRPI0416743A (sl) |
CA (1) | CA2545034C (sl) |
CY (1) | CY1119723T1 (sl) |
DK (2) | DK1687019T3 (sl) |
ES (2) | ES2727854T3 (sl) |
HK (1) | HK1246683B (sl) |
HU (2) | HUE038395T2 (sl) |
MX (1) | MXPA06005581A (sl) |
PL (2) | PL1687019T3 (sl) |
PT (2) | PT3300721T (sl) |
RU (1) | RU2421238C2 (sl) |
SI (2) | SI3300721T1 (sl) |
TR (1) | TR201906789T4 (sl) |
WO (1) | WO2005049061A2 (sl) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60224284T2 (de) * | 2001-06-28 | 2008-12-18 | Novo Nordisk A/S | Stabile formulierung von modifiziertem glp-1 |
CN104826116A (zh) * | 2003-11-20 | 2015-08-12 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
KR101699370B1 (ko) | 2006-09-22 | 2017-02-14 | 노보 노르디스크 에이/에스 | 프로테아제 내성 인슐린 유사체 |
CN101674812B (zh) | 2007-04-30 | 2013-12-11 | 诺沃-诺迪斯克有限公司 | 干燥蛋白组合物的方法、干燥的蛋白组合物和包含干燥的蛋白的药物组合物 |
EP2514406A1 (en) * | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
WO2008145730A1 (en) * | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | Stable non-aqueous pharmaceutical compositions |
EP2254905B1 (en) | 2008-03-14 | 2016-12-14 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
WO2009115469A1 (en) | 2008-03-18 | 2009-09-24 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
EP2111871A1 (de) * | 2008-04-26 | 2009-10-28 | Sandoz AG | Stabilisierte Flüssigformulierung |
US8031419B2 (en) | 2009-07-28 | 2011-10-04 | Hong Kong Applied Science and Technology Research Institute, Co., Ltd. | Compact imaging device |
US20110097386A1 (en) * | 2009-10-22 | 2011-04-28 | Biodel, Inc. | Stabilized glucagon solutions |
US9610329B2 (en) * | 2009-10-22 | 2017-04-04 | Albireo Pharma, Inc. | Stabilized glucagon solutions |
US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
US9061037B2 (en) | 2010-03-18 | 2015-06-23 | Innopharma, Inc. | Stable bortezomib formulations |
RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
CN106117344B (zh) | 2011-04-12 | 2020-11-03 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
EP3053590A1 (fr) * | 2011-08-10 | 2016-08-10 | Adocia | Solution injectable d'au moins une insuline basale |
US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
WO2013153000A2 (en) | 2012-04-11 | 2013-10-17 | Novo Nordisk A/S | Insulin formulations |
EP2863895B1 (en) | 2012-06-20 | 2021-04-14 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
MX366405B (es) | 2012-07-01 | 2019-07-08 | Novo Nordisk As | Uso de peptidos glp-1 de accion prolongada. |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
ES2688367T3 (es) | 2012-12-21 | 2018-11-02 | Sanofi | Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
TWI780236B (zh) * | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
US9738697B2 (en) | 2013-06-23 | 2017-08-22 | Wisconsin Alumni Research Foundation | Alpha/beta-polypeptide analogs of glucagon-like peptide-1 |
CN104415326A (zh) * | 2013-08-28 | 2015-03-18 | 深圳翰宇药业股份有限公司 | 一种含有利拉鲁肽的药物制剂组合物及其制备方法 |
AU2014333979B2 (en) | 2013-10-07 | 2018-02-15 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
CN112957455A (zh) | 2014-01-09 | 2021-06-15 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
WO2016038521A1 (en) * | 2014-09-08 | 2016-03-17 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of liraglutide |
WO2016059593A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of protein drugs and process for its preparation |
CN107249620B (zh) * | 2015-05-13 | 2018-06-26 | 杭州九源基因工程有限公司 | 一种包含glp-1类似物的药物制剂及其制备方法 |
LT3297653T (lt) | 2015-05-22 | 2022-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
JP2019506440A (ja) * | 2016-03-01 | 2019-03-07 | 深▲せん▼翰宇薬業股▲ふん▼有限公司Hybio Pharmaceutical Co., Ltd. | 医薬組成物及びその製造方法 |
US10653753B2 (en) | 2016-03-04 | 2020-05-19 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
CN108883158A (zh) * | 2016-03-04 | 2018-11-23 | 诺和诺德股份有限公司 | 用于肾脏病况的利拉鲁肽 |
US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
EA201990071A1 (ru) * | 2016-06-20 | 2019-06-28 | АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В. | Композиция пептидной вакцины |
US10350293B2 (en) | 2016-08-23 | 2019-07-16 | Pharmacotherapia d.o.o. | Compositions and methods for treating symptoms associated with multiple sclerosis |
US20190224122A1 (en) | 2016-09-23 | 2019-07-25 | Delpor, Inc. | Stable compositions for incretin mimetic compounds |
BR112019010236A2 (pt) | 2016-11-21 | 2019-08-20 | Eiger Biopharmaceuticals Inc | formulações tamponadas de exendina (9-39) |
HUE055231T2 (hu) | 2016-12-16 | 2021-11-29 | Novo Nordisk As | Inzulint tartalmazó gyógyászati készítmények |
GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
TWI762706B (zh) * | 2017-08-24 | 2022-05-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1組成物及其用途 |
EP3746111B1 (en) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
WO2019200594A1 (zh) | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
TWI705820B (zh) * | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
EP3628682A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
US11058745B1 (en) | 2018-10-04 | 2021-07-13 | Good Health, Llc | Stable liquid pharmaceutical compositions of daptomycin |
EP3863607A4 (en) * | 2018-10-09 | 2022-07-06 | Dat Tran | COMPOSITIONS AND METHODS TO ENHANCE THE SYSTEMIC DELIVERY, TOLERANCE AND EFFICACY OF CATIONIC MACROCYCLIC PEPTIDES |
HUE062893T2 (hu) * | 2018-10-26 | 2023-12-28 | Novo Nordisk As | Stabil szemaglutid kompozíciók, és alkalmazásaik |
WO2020127476A1 (en) | 2018-12-19 | 2020-06-25 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising glp-1 analogue |
US11471512B2 (en) | 2019-03-01 | 2022-10-18 | Merck Sharp & Dohme Llc | Pharmaceutical compositions of a peptide |
WO2020208541A1 (en) * | 2019-04-08 | 2020-10-15 | Enzene Biosciences Limited | Composition comprising glp-1 analogue |
WO2021123228A1 (en) | 2019-12-18 | 2021-06-24 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising glp-1 analogue |
WO2021144476A1 (en) | 2020-02-18 | 2021-07-22 | Novo Nordisk A/S | Pharmaceutical formulations |
EP4126004A1 (en) | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Agonist combination |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
AU2022263996A1 (en) | 2021-04-27 | 2023-11-02 | Aardvark Therapeutics, Inc. | Combination of bitter receptor agonist and gut-signaling compound |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH17800A (en) | 1980-03-21 | 1984-12-13 | Wellcome Found | Stabilized ophthalmic formulation |
US4483849A (en) | 1983-01-07 | 1984-11-20 | Carter William A | Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product |
US4468346A (en) * | 1983-10-27 | 1984-08-28 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibodies to porcine immunoglobulins |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
CA1341320C (en) | 1986-05-05 | 2001-11-20 | Joel Habener | Insulinotropic hormone |
DE3885459T2 (de) * | 1987-05-14 | 1994-03-24 | Commw Scient Ind Res Org | Molkeproteinfraktionen. |
JPH03505401A (ja) | 1988-06-27 | 1991-11-28 | ジェネックス・コーポレーション | 組換えタンパク質の培養培地への熱放出 |
DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
KR910700262A (ko) | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
EP0464022B1 (en) | 1989-03-20 | 2000-05-31 | The General Hospital Corporation | Insulinotropic hormone |
JP2822447B2 (ja) * | 1989-05-19 | 1998-11-11 | 住友電気工業株式会社 | 酸化物超電導線材の製造方法および装置 |
US5216011A (en) | 1989-09-01 | 1993-06-01 | Bristol-Myers Squibb Co. | Stable solutions of mitomycin c |
EP0431679B1 (en) | 1989-12-05 | 1994-10-19 | Merck & Co. Inc. | Method of stabilizing recombinant hepatitis B virus surface proteins from yeast |
DE69129226T2 (de) | 1990-01-24 | 1998-07-30 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
DE4002066A1 (de) | 1990-01-25 | 1991-08-01 | Basf Ag | Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen |
DE69103120T2 (de) * | 1990-10-26 | 1995-03-30 | Furukawa Electric Co Ltd | Polyphenylensulfid-Zusammensetzung für Pulverbeschichtung. |
US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
SE9101381D0 (sv) * | 1991-05-07 | 1991-05-07 | Tomas Moks | Peptide hormone solution |
US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
DK36492D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Praeparat |
DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
ES2098739T3 (es) | 1992-05-13 | 1997-05-01 | Sandoz Ltd | Composiciones oftalmicas conteniendo una cyclosporin. |
US6284727B1 (en) * | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
ES2130428T3 (es) | 1993-06-21 | 1999-07-01 | Novo Nordisk As | Cristales de insulina asp-b28. |
AU7531094A (en) * | 1993-08-24 | 1995-03-21 | Novo Nordisk A/S | Protracted glp-1 |
ATE204882T1 (de) | 1993-09-17 | 2001-09-15 | Novo Nordisk As | Acyliertes insulin |
US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
GB9320782D0 (en) * | 1993-10-08 | 1993-12-01 | Univ Leeds Innovations Ltd | Stabilising of proteins on solution |
PT729362E (pt) * | 1993-11-19 | 2000-06-30 | Searle & Co | Composicao transdermica de n-¬n-¬5-¬4-(aminoiminometil)fenil|-1oxopentil|-l-alfa-aspartil|-l-fenillalanina ou esteres e seus sais farmaceuticamente aceitaveis |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
WO1995022560A1 (en) | 1994-02-22 | 1995-08-24 | The Syntex-Synergen Neuroscience Joint Venture | Pharmaceutical formulations of cntf |
US5652216A (en) * | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
US5504188A (en) | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
DE69532492T2 (de) | 1994-08-31 | 2004-12-02 | Mitsubishi Pharma Corp. | Verfahren zur Reinigung von rekombinantem menschlichem Serumalbumin |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
DE69529998D1 (de) | 1994-12-23 | 2003-04-24 | Novo Nordisk As | Glp-1 zusammensetzungen mit verlängerter wirkdauer |
WO1996024369A1 (en) | 1995-02-06 | 1996-08-15 | Genetics Institute, Inc. | Formulations for il-12 |
US5834428A (en) * | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US6184201B1 (en) * | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
DE69626976T2 (de) | 1995-06-02 | 2004-03-04 | Novozymes A/S | BEHANDLUNG EINER PROTEINLÖSUNG MIT A1/Fe UND ANSCHLIESENDE MEMBRANKONZENTRATION |
US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
WO1997046584A1 (de) | 1996-06-05 | 1997-12-11 | Boehringer Mannheim Gmbh | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel |
SK284490B6 (sk) * | 1996-07-03 | 2005-05-05 | Alza Corporation | Stabilná nevodná formulácia a spôsob jej prípravy |
US5981489A (en) | 1996-07-18 | 1999-11-09 | Alza Corporation | Non-aqueous protic peptide formulations |
JPH10101696A (ja) | 1996-08-08 | 1998-04-21 | Shinotesuto:Kk | 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質 |
CA2262647C (en) | 1996-08-08 | 2007-12-04 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
US6384016B1 (en) * | 1998-03-13 | 2002-05-07 | Novo Nordisk A/S | Stabilized aqueous peptide solutions |
BRPI9711437B8 (pt) | 1996-08-30 | 2021-05-25 | Novo Nordisk As | derivados de glp-1 |
US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
ES2247676T3 (es) | 1997-01-07 | 2006-03-01 | Amylin Pharmaceuticals, Inc. | Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia. |
NZ336793A (en) | 1997-01-20 | 2000-08-25 | Japan Energy Corp | Method for stabilizing peptides by adding an organic acid and then lyophilizing the peptide mixture |
AU6586298A (en) | 1997-03-31 | 1998-10-22 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
CA2236519C (en) * | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
ZA984697B (en) | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
AU4894697A (en) | 1997-10-01 | 1999-04-23 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
AU740665B2 (en) | 1997-10-24 | 2001-11-08 | Genentech Inc. | Purification of molecules |
CA2312190A1 (en) | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | Glp-1 formulations |
MY120063A (en) | 1997-12-09 | 2005-08-30 | Lilly Co Eli | Stabilized teriparatide solutions |
US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
DE69942307D1 (de) | 1998-02-27 | 2010-06-10 | Novo Nordisk As | N-terminal veränderte glp-1 abkömmlinge |
JP2002508162A (ja) | 1998-02-27 | 2002-03-19 | ノボ ノルディスク アクティーゼルスカブ | N末端を短縮したglp−1誘導体 |
JP2002504518A (ja) | 1998-02-27 | 2002-02-12 | ノボ ノルディスク アクティーゼルスカブ | 部分的に構造化されたミセルー様凝集体を形成する、25%を超えるヘリックス−含有率を有するglp−1誘導体 |
EP1056775B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
EP1060191B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
CN1317967A (zh) | 1998-09-17 | 2001-10-17 | 伊莱利利公司 | 蛋白质制剂 |
AU2373400A (en) | 1998-12-22 | 2000-07-12 | Eli Lilly And Company | Shelf-stable formulation of glucagon-like peptide-1 |
DE122007000001I1 (de) | 1999-01-14 | 2007-06-28 | Amylin Pharmaceuticals Inc | Neue exendin agonist Formulierungen und deren Verabreichung |
US6444788B1 (en) * | 1999-03-15 | 2002-09-03 | Novo Nordisk A/S | Ion exchange chromatography of GLP-1, analogs and derivatives thereof |
ATE409193T1 (de) | 1999-03-17 | 2008-10-15 | Novo Nordisk As | Verfahren zur acylierung von peptiden und proteinen |
EP1196189A2 (en) | 1999-06-25 | 2002-04-17 | Medtronic MiniMed, Inc. | Multiple agent diabetes therapy |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
ATE309820T1 (de) | 1999-09-20 | 2005-12-15 | Lilly Co Eli | Verwendung einer parathyroidhormone zur reduktion des krebsrisikos |
BR0016334A (pt) | 1999-12-16 | 2002-09-10 | Lilly Co Eli | Composições de polipeptìdeo com estabilidade aperfeiçoada |
US7022674B2 (en) * | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
US20010012829A1 (en) * | 2000-01-11 | 2001-08-09 | Keith Anderson | Transepithelial delivery GLP-1 derivatives |
AU2353701A (en) | 2000-01-11 | 2001-07-24 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
WO2001052937A1 (en) | 2000-01-24 | 2001-07-26 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
EP1396499A3 (en) | 2000-01-27 | 2004-12-29 | Eli Lilly And Company | Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds |
EP1257577B1 (en) | 2000-01-27 | 2004-04-21 | Eli Lilly And Company | Process for solubilizing glucagon-like peptide 1 (glp-1) compounds |
US6569901B2 (en) * | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
US6844321B2 (en) * | 2000-01-31 | 2005-01-18 | Novo Nordisk A/S | Crystallization of a GLP-1 analogue |
WO2001077141A1 (en) | 2000-04-06 | 2001-10-18 | Novo Nordisk A/S | Shock heat treatment of polypeptides |
EA008837B1 (ru) | 2000-06-16 | 2007-08-31 | Эли Лилли Энд Компани | Аналоги глюкагоноподобного пептида и их применение |
JP4798833B2 (ja) | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | 加熱処理工程を含むヒト血清アルブミンの製造方法 |
WO2002046227A2 (en) | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
AU2002239384B2 (en) | 2000-12-13 | 2007-01-11 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
WO2002048192A2 (en) | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
US20020151467A1 (en) * | 2000-12-21 | 2002-10-17 | Leung Frank K. | Methods and compositions for oral insulin delivery |
GB2371227A (en) * | 2001-01-10 | 2002-07-24 | Grandis Biotech Gmbh | Crystallisation - resistant aqueous growth hormone formulations |
EA006160B1 (ru) * | 2001-02-16 | 2005-10-27 | Конджачем, Инк. | Долгоживущий глюкагоноподобный пептид 2(glp-2, гпп-2) для лечения желудочно-кишечных заболеваний и расстройств |
US6573237B2 (en) * | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
WO2002074978A2 (en) * | 2001-03-19 | 2002-09-26 | President And Fellows Of Harvard College | Nucleic acid shuffling |
US20040156835A1 (en) * | 2001-05-30 | 2004-08-12 | Taiji Imoto | Protein preparation |
DE60224284T2 (de) | 2001-06-28 | 2008-12-18 | Novo Nordisk A/S | Stabile formulierung von modifiziertem glp-1 |
US6872705B2 (en) | 2001-07-13 | 2005-03-29 | Allergan, Inc. | Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions |
CN1335182A (zh) * | 2001-08-08 | 2002-02-13 | 华中科技大学 | 胰岛素口腔喷剂及其制备工艺 |
MXPA04001560A (es) * | 2001-08-28 | 2004-05-17 | Lilly Co Eli | Premezclas de glp-1 e insulina basal. |
KR20040054729A (ko) | 2001-10-18 | 2004-06-25 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도 |
US7179788B2 (en) | 2001-10-19 | 2007-02-20 | Eli Lilly And Company | Biphasic mixtures of GLP-1 and insulin |
DK1344533T3 (da) | 2002-03-15 | 2007-01-08 | Natimmune As | Farmaceutiske præparater, der omfatter mannosebindende lectin |
AU2003226913A1 (en) * | 2002-04-04 | 2003-10-20 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
AU2003266216A1 (en) | 2002-09-25 | 2004-04-19 | Novo Nordisk A/S | Purification process comprising microfiltration at elevated temperatures |
US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
WO2004089985A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Stable pharmaceutical compositions |
EP1631308B1 (en) | 2003-05-30 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
WO2004105781A2 (en) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
WO2005046716A1 (en) * | 2003-11-13 | 2005-05-26 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia |
CN104826116A (zh) * | 2003-11-20 | 2015-08-12 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
ES2575984T3 (es) * | 2004-11-12 | 2016-07-04 | Novo Nordisk A/S | Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal |
GB0704846D0 (en) * | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
MX364229B (es) * | 2011-02-04 | 2019-04-17 | Infirst Healthcare Ltd | Composiciones y metodos para tratar enfermedades cardiovasculares. |
CN102579350B (zh) * | 2012-03-02 | 2013-04-24 | 海南灵康制药有限公司 | 右旋布洛芬脂质体固体制剂 |
-
2004
- 2004-11-18 CN CN201510078513.9A patent/CN104826116A/zh active Pending
- 2004-11-18 KR KR1020067009738A patent/KR101243648B1/ko active Protection Beyond IP Right Term
- 2004-11-18 CA CA2545034A patent/CA2545034C/en not_active Expired - Fee Related
- 2004-11-18 EP EP04797453.0A patent/EP1687019B1/en active Active
- 2004-11-18 DK DK04797453.0T patent/DK1687019T3/en active
- 2004-11-18 WO PCT/DK2004/000792 patent/WO2005049061A2/en active Application Filing
- 2004-11-18 CN CN2012102947168A patent/CN102784386A/zh active Pending
- 2004-11-18 RU RU2006116414/15A patent/RU2421238C2/ru active Protection Beyond IP Right Term
- 2004-11-18 PT PT17196501T patent/PT3300721T/pt unknown
- 2004-11-18 PT PT47974530T patent/PT1687019T/pt unknown
- 2004-11-18 CN CN200480034152.8A patent/CN1882356B/zh active Active
- 2004-11-18 BR BRPI0416743-0A patent/BRPI0416743A/pt not_active Application Discontinuation
- 2004-11-18 SI SI200432469T patent/SI3300721T1/sl unknown
- 2004-11-18 PL PL04797453T patent/PL1687019T3/pl unknown
- 2004-11-18 TR TR2019/06789T patent/TR201906789T4/tr unknown
- 2004-11-18 JP JP2006540168A patent/JP5558655B2/ja active Active
- 2004-11-18 ES ES17196501T patent/ES2727854T3/es active Active
- 2004-11-18 ES ES04797453.0T patent/ES2660320T3/es active Active
- 2004-11-18 HU HUE04797453A patent/HUE038395T2/hu unknown
- 2004-11-18 CN CN202110402074.8A patent/CN113304250A/zh not_active Withdrawn
- 2004-11-18 SI SI200432419T patent/SI1687019T1/sl unknown
- 2004-11-18 EP EP11157594.0A patent/EP2394656B1/en active Active
- 2004-11-18 EP EP17196501.5A patent/EP3300721B1/en active Active
- 2004-11-18 MX MXPA06005581A patent/MXPA06005581A/es active IP Right Grant
- 2004-11-18 HU HUE17196501A patent/HUE043210T2/hu unknown
- 2004-11-18 DK DK17196501.5T patent/DK3300721T3/da active
- 2004-11-18 PL PL17196501T patent/PL3300721T3/pl unknown
- 2004-11-18 AU AU2004290862A patent/AU2004290862B2/en active Active
-
2006
- 2006-05-17 US US11/435,977 patent/US8114833B2/en active Active
-
2012
- 2012-01-31 US US13/362,745 patent/US20120225810A1/en not_active Abandoned
- 2012-03-29 JP JP2012077335A patent/JP5670373B2/ja active Active
-
2018
- 2018-01-03 CY CY20181100004T patent/CY1119723T1/el unknown
- 2018-05-16 HK HK18106312.8A patent/HK1246683B/zh unknown
-
2019
- 2019-01-29 US US16/260,204 patent/US20190231876A1/en not_active Abandoned
-
2020
- 2020-06-24 US US16/910,945 patent/US20200316204A1/en not_active Abandoned
-
2022
- 2022-12-09 US US18/078,518 patent/US20230364241A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1687019T1 (sl) | Propilen gliko-ki vsebuje peptidne formulacije, ki so optimalne za proizvodnjo in za uporabo v injekcijskih napravah | |
JP6258368B2 (ja) | 医薬組成物および関連する送達方法 | |
CN101141975B (zh) | Vegf拮抗剂制剂 | |
PE20050438A1 (es) | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos | |
JP7038655B2 (ja) | Il-2医薬組成物 | |
CN1172658C (zh) | 蛋白质制剂 | |
WO2011012637A4 (en) | Subcutaneous anti-her2 antibody formulation | |
PE20071063A1 (es) | Formulaciones de proteinas estables | |
RU2007119724A (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
BR0011772A (pt) | Conjugado de droga-oligÈmero, composição farmacêutica, método de solubilização de uma droga em uma microemulsão, e, métodos para fornecer um conjugado de droga ativa - hidrófilo e um conjugado de droga ativa - peg a um sìtio de um indivìduo | |
RU2008142359A (ru) | Композиция человеческого моноклонального антитела к igf-1r | |
CN109789088A (zh) | 新制剂 | |
CN104768569A (zh) | 具有PEG干扰素α-2b的稳定的药物组合物 | |
WO2005089503A3 (en) | Cd4-igg2 formulations | |
MX2021014332A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-angptl3. | |
UA93365C2 (ru) | Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты) | |
CN1802171A (zh) | 不包含血清白蛋白的人红细胞生成素的稳定水溶液 | |
JP2004538275A5 (sl) | ||
US20210346463A1 (en) | Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides | |
CN1960746A (zh) | 稳定性提高的含生物分子配方 | |
JP2016535015A5 (sl) | ||
RU2008125169A (ru) | Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента грелин и его производные или вещество, воздействующее на рецептор ghs-r1а | |
WO2016048189A1 (ru) | Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении | |
US20210330801A1 (en) | Novel protein drug conjugate formulation |